» Articles » PMID: 37119745

TRIM28 Negatively Regulates the RLR Signaling Pathway by Targeting MAVS for Degradation Via K48-linked Polyubiquitination

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2023 Apr 29
PMID 37119745
Authors
Affiliations
Soon will be listed here.
Abstract

Mitochondrial antiviral signaling (MAVS) protein is a core signaling adapter in the retinoid acid-inducible gene-I-like receptor (RLR) signaling pathway that recruits downstream signaling factors, ultimately leading to the activation of type Ⅰ interferons. However, the mechanisms that modulate the RLR signaling pathway by manipulating MAVS are not fully understood. Previous studies suggested that tripartite motif 28 (TRIM28) participates in regulating innate immune signaling pathways by inhibiting the expression of immune-related genes at the transcriptional level. In this study, we characterized TRIM28 as a negative regulator of the RLR signaling pathway in a MAVS-dependent manner. Overexpression of TRIM28 inhibited the MAVS-induced production of type Ⅰ interferons and proinflammatory cytokines, while knocking down TRIM28 exerted the opposite effect. Mechanistically, TRIM28 targeted MAVS for proteasome-mediated degradation via K48-linked polyubiquitination. The RING domain of TRIM28, especially the cysteine residues at positions 65 and 68, was critical for the suppressive effect of TRIM28 on MAVS-mediated RLR signaling, while each of the C-terminal domains of TRIM28 contributed to its interaction with MAVS. Further investigation revealed that TRIM28 transferred ubiquitin chains to the K7, K10, K371, K420, and K500 residues of MAVS. Together, our results reveal a previously uncharacterized mechanism involving TRIM28 in fine-tuning innate immune responses and provide new insights into the mechanisms by which MAVS is regulated, which contribute to the understanding of the molecular mechanisms underlying immune homeostasis maintenance.

Citing Articles

Exploring the role of mitochondrial antiviral signaling protein in cardiac diseases.

Qi Y, Yin J, Xia W, Yang S Front Immunol. 2025; 16:1540774.

PMID: 40040697 PMC: 11876050. DOI: 10.3389/fimmu.2025.1540774.


TRIM28 functions as SUMO ligase to SUMOylate TRAF6 and regulate NF-κB activation in HBV-replicating cells.

Yang Y, Wang T, Fu Y, Li X, Yu F Hepatol Int. 2025; .

PMID: 39920527 DOI: 10.1007/s12072-025-10779-6.


Palmitoylation acts as a checkpoint for MAVS aggregation to promote antiviral innate immune responses.

Wang L, Li M, Lian G, Yang S, Cai J, Cai Z J Clin Invest. 2024; 134(23).

PMID: 39621307 PMC: 11601910. DOI: 10.1172/JCI177924.


PBLD enhances antiviral innate immunity by promoting the p53-USP4-MAVS signaling axis.

Chu F, Hou P, Zhu H, Gao Y, Wang X, He W Proc Natl Acad Sci U S A. 2024; 121(49):e2401174121.

PMID: 39589880 PMC: 11626120. DOI: 10.1073/pnas.2401174121.


Immune Checkpoint VISTA Negatively Regulates Microglia Glycolysis and Activation via TRIM28-Mediated Ubiquitination of HK2 in Sepsis-Associated Encephalopathy.

Xu Y, Zhu Y, Shi Y, Ye B, Bo L, Tao T Mol Neurobiol. 2024; 62(4):4452-4465.

PMID: 39455538 DOI: 10.1007/s12035-024-04572-z.